Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 972

1.

Genetic deletion of muscle RANK or selective inhibition of RANKL is not as effective as full-length OPG-fc in mitigating muscular dystrophy.

Dufresne SS, Boulanger-Piette A, Bossé S, Argaw A, Hamoudi D, Marcadet L, Gamu D, Fajardo VA, Yagita H, Penninger JM, Russell Tupling A, Frenette J.

Acta Neuropathol Commun. 2018 Apr 24;6(1):31. doi: 10.1186/s40478-018-0533-1.

2.

Antigen-specific Helios- , Neuropilin-1- Tregs induce apoptosis of autoreactive B cells via PD-L1.

Gotot J, Dhana E, Yagita H, Kaiser R, Ludwig-Portugall I, Kurts C.

Immunol Cell Biol. 2018 Apr 4. doi: 10.1111/imcb.12053. [Epub ahead of print]

PMID:
29617057
3.

Blockade of TNF receptor superfamily 1 (TNFR1)-dependent and TNFR1-independent cell death is crucial for normal epidermal differentiation.

Piao X, Miura R, Miyake S, Komazawa-Sakon S, Koike M, Shindo R, Takeda J, Hasegawa A, Abe R, Nishiyama C, Mikami T, Yagita H, Uchiyama Y, Nakano H.

J Allergy Clin Immunol. 2018 Mar 27. pii: S0091-6749(18)30446-9. doi: 10.1016/j.jaci.2018.02.043. [Epub ahead of print]

PMID:
29596938
4.

Anti-CD11b antibody treatment suppresses the osteoclast generation, inflammatory cell infiltration, and autoantibody production in arthritis-prone FcγRIIB-deficient mice.

Ohtsuji M, Lin Q, Okazaki H, Takahashi K, Amano H, Yagita H, Nishimura H, Hirose S.

Arthritis Res Ther. 2018 Feb 8;20(1):25. doi: 10.1186/s13075-018-1523-1.

5.

Perforin proteostasis is regulated through its C2 domain: supra-physiological cell death mediated by T431D-perforin.

Brennan AJ, Law RHP, Conroy PJ, Noori T, Lukoyanova N, Saibil H, Yagita H, Ciccone A, Verschoor S, Whisstock JC, Trapani JA, Voskoboinik I.

Cell Death Differ. 2018 Feb 7. doi: 10.1038/s41418-018-0057-z. [Epub ahead of print]

PMID:
29416110
6.

The CD300e molecule in mice is an immune-activating receptor.

Isobe M, Izawa K, Sugiuchi M, Sakanishi T, Kaitani A, Takamori A, Maehara A, Matsukawa T, Takahashi M, Yamanishi Y, Oki T, Uchida S, Uchida K, Ando T, Maeda K, Nakano N, Yagita H, Takai T, Ogawa H, Okumura K, Kitamura T, Kitaura J.

J Biol Chem. 2018 Mar 9;293(10):3793-3805. doi: 10.1074/jbc.RA117.000696. Epub 2018 Jan 22.

PMID:
29358324
7.

Editorial: Ying and Yang Members of the Tumor Necrosis Factor Superfamily: Friends or Foes in Immune-Mediated Diseases and Cancer.

Giwa A, Ahmed R, Donner T, Yagita H, Hamad ARA.

Front Immunol. 2017 Nov 23;8:1584. doi: 10.3389/fimmu.2017.01584. eCollection 2017. No abstract available.

8.

A variant of death-receptor 3 associated with rheumatoid arthritis interferes with apoptosis-induction of T cell.

Hashiramoto A, Konishi Y, Murayama K, Kawasaki H, Yoshida K, Tsumiyama K, Tanaka K, Mizuhara M, Shiotsuki T, Kitamura H, Komai K, Kimura T, Yagita H, Shiozawa K, Shiozawa S.

J Biol Chem. 2018 Feb 9;293(6):1933-1943. doi: 10.1074/jbc.M117.798884. Epub 2017 Nov 27.

9.

Autophagy-dependent regulation of tumor metastasis by myeloid cells.

Jinushi M, Morita T, Xu Z, Kinoshita I, Dosaka-Akita H, Yagita H, Kawakami Y.

PLoS One. 2017 Jul 7;12(7):e0179357. doi: 10.1371/journal.pone.0179357. eCollection 2017.

10.

Concurrent OX40 and CD30 Ligand Blockade Abrogates the CD4-Driven Autoimmunity Associated with CTLA4 and PD1 Blockade while Preserving Excellent Anti-CD8 Tumor Immunity.

Nawaf MG, Ulvmar MH, Withers DR, McConnell FM, Gaspal FM, Webb GJ, Jones ND, Yagita H, Allison JP, Lane PJL.

J Immunol. 2017 Aug 1;199(3):974-981. doi: 10.4049/jimmunol.1700088. Epub 2017 Jun 23.

11.

Identification of an immunogenic neo-epitope encoded by mouse sarcoma using CXCR3 ligand mRNAs as sensors.

Fujii K, Miyahara Y, Harada N, Muraoka D, Komura M, Yamaguchi R, Yagita H, Nakamura J, Sugino S, Okumura S, Imoto S, Miyano S, Shiku H.

Oncoimmunology. 2017 Mar 20;6(5):e1306617. doi: 10.1080/2162402X.2017.1306617. eCollection 2017.

12.

Co-administration of RANKL and CTLA4 Antibodies Enhances Lymphocyte-Mediated Antitumor Immunity in Mice.

Ahern E, Harjunpää H, Barkauskas D, Allen S, Takeda K, Yagita H, Wyld D, Dougall WC, Teng MWL, Smyth MJ.

Clin Cancer Res. 2017 Oct 1;23(19):5789-5801. doi: 10.1158/1078-0432.CCR-17-0606. Epub 2017 Jun 20.

PMID:
28634284
13.

Expansion of FasL-Expressing CD5+ B Cells in Type 1 Diabetes Patients.

Saxena A, Yagita H, Donner TW, Hamad ARA.

Front Immunol. 2017 Apr 7;8:402. doi: 10.3389/fimmu.2017.00402. eCollection 2017.

14.

An Anti-Programmed Death-1 Antibody (αPD-1) Fusion Protein That Self-Assembles into a Multivalent and Functional αPD-1 Nanoparticle.

Zhao P, Atanackovic D, Dong S, Yagita H, He X, Chen M.

Mol Pharm. 2017 May 1;14(5):1494-1500. doi: 10.1021/acs.molpharmaceut.6b01021. Epub 2017 Apr 19.

15.

Notch Ligand DLL4 Alleviates Allergic Airway Inflammation via Induction of a Homeostatic Regulatory Pathway.

Huang MT, Chen YL, Lien CI, Liu WL, Hsu LC, Yagita H, Chiang BL.

Sci Rep. 2017 Mar 6;7:43535. doi: 10.1038/srep43535.

16.

PD-1 modulates regulatory T-cell homeostasis during low-dose interleukin-2 therapy.

Asano T, Meguri Y, Yoshioka T, Kishi Y, Iwamoto M, Nakamura M, Sando Y, Yagita H, Koreth J, Kim HT, Alyea EP, Armand P, Cutler CS, Ho VT, Antin JH, Soiffer RJ, Maeda Y, Tanimoto M, Ritz J, Matsuoka KI.

Blood. 2017 Apr 13;129(15):2186-2197. doi: 10.1182/blood-2016-09-741629. Epub 2017 Feb 1.

17.

Radiation-Induced Enhancement of Antitumor T-cell Immunity by VEGF-Targeted 4-1BB Costimulation.

Schrand B, Verma B, Levay A, Patel S, Castro I, Benaduce AP, Brenneman R, Umland O, Yagita H, Gilboa E, Ishkanian A.

Cancer Res. 2017 Mar 15;77(6):1310-1321. doi: 10.1158/0008-5472.CAN-16-2105. Epub 2017 Jan 12.

18.

Protective Role of ICOS and ICOS Ligand in Corneal Transplantation and in Maintenance of Immune Privilege.

Kunishige T, Taniguchi H, Terada M, Akiba H, Yagita H, Abe R, Hori J.

Invest Ophthalmol Vis Sci. 2016 Dec 1;57(15):6815-6823. doi: 10.1167/iovs.16-20644.

PMID:
28002569
19.

TRAIL signaling is proinflammatory and proviral in a murine model of rhinovirus 1B infection.

Girkin JL, Hatchwell LM, Collison AM, Starkey MR, Hansbro PM, Yagita H, Foster PS, Mattes J.

Am J Physiol Lung Cell Mol Physiol. 2017 Jan 1;312(1):L89-L99. doi: 10.1152/ajplung.00200.2016. Epub 2016 Nov 11.

20.

SCIB1, a huIgG1 antibody DNA vaccination, combined with PD-1 blockade induced efficient therapy of poorly immunogenic tumors.

Xue W, Brentville VA, Symonds P, Cook KW, Yagita H, Metheringham RL, Durrant LG.

Oncotarget. 2016 Dec 13;7(50):83088-83100. doi: 10.18632/oncotarget.13070.

21.

Agonistic CD40 mAb-Driven IL12 Reverses Resistance to Anti-PD1 in a T-cell-Rich Tumor.

Ngiow SF, Young A, Blake SJ, Hill GR, Yagita H, Teng MW, Korman AJ, Smyth MJ.

Cancer Res. 2016 Nov 1;76(21):6266-6277. Epub 2016 Sep 9.

22.

Acute Virus Control Mediated by Licensed NK Cells Sets Primary CD8+ T Cell Dependence on CD27 Costimulation.

Teoh JJ, Gamache AE, Gillespie AL, Stadnisky MD, Yagita H, Bullock TN, Brown MG.

J Immunol. 2016 Dec 1;197(11):4360-4370. Epub 2016 Oct 24.

23.

Tumor Eradication by Cisplatin Is Sustained by CD80/86-Mediated Costimulation of CD8+ T Cells.

Beyranvand Nejad E, van der Sluis TC, van Duikeren S, Yagita H, Janssen GM, van Veelen PA, Melief CJ, van der Burg SH, Arens R.

Cancer Res. 2016 Oct 15;76(20):6017-6029. Epub 2016 Aug 28.

24.

Pharmacologic inhibition of Notch signaling suppresses food antigen-induced mucosal mast cell hyperplasia.

Honjo A, Nakano N, Yamazaki S, Hara M, Uchida K, Kitaura J, Nishiyama C, Yagita H, Ohtsuka Y, Ogawa H, Okumura K, Shimizu T.

J Allergy Clin Immunol. 2017 Mar;139(3):987-996.e10. doi: 10.1016/j.jaci.2016.05.046. Epub 2016 Jul 16.

PMID:
27555456
25.

SCIB2, an antibody DNA vaccine encoding NY-ESO-1 epitopes, induces potent antitumor immunity which is further enhanced by checkpoint blockade.

Xue W, Metheringham RL, Brentville VA, Gunn B, Symonds P, Yagita H, Ramage JM, Durrant LG.

Oncoimmunology. 2016 Apr 22;5(6):e1169353. doi: 10.1080/2162402X.2016.1169353. eCollection 2016 Jun.

26.

Microfold Cells Actively Translocate Mycobacterium tuberculosis to Initiate Infection.

Nair VR, Franco LH, Zacharia VM, Khan HS, Stamm CE, You W, Marciano DK, Yagita H, Levine B, Shiloh MU.

Cell Rep. 2016 Aug 2;16(5):1253-1258. doi: 10.1016/j.celrep.2016.06.080. Epub 2016 Jul 21.

27.

IL-17A-producing CD30(+) Vδ1 T cells drive inflammation-induced cancer progression.

Kimura Y, Nagai N, Tsunekawa N, Sato-Matsushita M, Yoshimoto T, Cua DJ, Iwakura Y, Yagita H, Okada F, Tahara H, Saiki I, Irimura T, Hayakawa Y.

Cancer Sci. 2016 Sep;107(9):1206-14. doi: 10.1111/cas.13005. Epub 2016 Sep 1.

28.

Systemic DC Activation Modulates the Tumor Microenvironment and Shapes the Long-Lived Tumor-Specific Memory Mediated by CD8+ T Cells.

Shimizu K, Yamasaki S, Shinga J, Sato Y, Watanabe T, Ohara O, Kuzushima K, Yagita H, Komuro Y, Asakura M, Fujii S.

Cancer Res. 2016 Jul 1;76(13):3756-66. doi: 10.1158/0008-5472.CAN-15-3219.

29.

Differential contribution of three immune checkpoint (VISTA, CTLA-4, PD-1) pathways to antitumor responses against squamous cell carcinoma.

Kondo Y, Ohno T, Nishii N, Harada K, Yagita H, Azuma M.

Oral Oncol. 2016 Jun;57:54-60. doi: 10.1016/j.oraloncology.2016.04.005. Epub 2016 May 3.

PMID:
27208845
30.

Concomitant targeting of programmed death-1 (PD-1) and CD137 improves the efficacy of radiotherapy in a mouse model of human BRAFV600-mutant melanoma.

Kroon P, Gadiot J, Peeters M, Gasparini A, Deken MA, Yagita H, Verheij M, Borst J, Blank CU, Verbrugge I.

Cancer Immunol Immunother. 2016 Jun;65(6):753-63. doi: 10.1007/s00262-016-1843-4. Epub 2016 May 9.

31.

Programming of donor T cells using allogeneic δ-like ligand 4-positive dendritic cells to reduce GVHD in mice.

Mochizuki K, Meng L, Mochizuki I, Tong Q, He S, Liu Y, Purushe J, Fung H, Zaidi MR, Zhang Y, Reshef R, Blazar BR, Yagita H, Mineishi S, Zhang Y.

Blood. 2016 Jun 23;127(25):3270-80. doi: 10.1182/blood-2015-05-644476. Epub 2016 May 3.

32.

M-Cells Contribute to the Entry of an Oral Vaccine but Are Not Essential for the Subsequent Induction of Protective Immunity against Francisella tularensis.

Cunningham AL, Guentzel MN, Yu JJ, Hung CY, Forsthuber TG, Navara CS, Yagita H, Williams IR, Klose KE, Eaves-Pyles TD, Arulanandam BP.

PLoS One. 2016 Apr 21;11(4):e0153402. doi: 10.1371/journal.pone.0153402. eCollection 2016.

33.

Establishment of a Therapeutic Anti-Pan HLA-Class II Monoclonal Antibody That Directly Induces Lymphoma Cell Death via Large Pore Formation.

Matsuoka S, Ishii Y, Nakao A, Abe M, Ohtsuji N, Momose S, Jin H, Arase H, Sugimoto K, Nakauchi Y, Masutani H, Maeda M, Yagita H, Komatsu N, Hino O.

PLoS One. 2016 Mar 30;11(3):e0150496. doi: 10.1371/journal.pone.0150496. eCollection 2016.

34.

CD27 Agonism Plus PD-1 Blockade Recapitulates CD4+ T-cell Help in Therapeutic Anticancer Vaccination.

Ahrends T, Bąbała N, Xiao Y, Yagita H, van Eenennaam H, Borst J.

Cancer Res. 2016 May 15;76(10):2921-31. doi: 10.1158/0008-5472.CAN-15-3130. Epub 2016 Mar 28.

35.

Integrin-Alpha IIb Identifies Murine Lymph Node Lymphatic Endothelial Cells Responsive to RANKL.

Cordeiro OG, Chypre M, Brouard N, Rauber S, Alloush F, Romera-Hernandez M, Bénézech C, Li Z, Eckly A, Coles MC, Rot A, Yagita H, Léon C, Ludewig B, Cupedo T, Lanza F, Mueller CG.

PLoS One. 2016 Mar 24;11(3):e0151848. doi: 10.1371/journal.pone.0151848. eCollection 2016.

36.

Interleukin-1 is required for cancer eradication mediated by tumor-specific Th1 cells.

Haabeth OA, Lorvik KB, Yagita H, Bogen B, Corthay A.

Oncoimmunology. 2015 Jul 25;5(1):e1039763. eCollection 2016.

37.

TGFβ-dependent expression of PD-1 and PD-L1 controls CD8(+) T cell anergy in transplant tolerance.

Baas M, Besançon A, Goncalves T, Valette F, Yagita H, Sawitzki B, Volk HD, Waeckel-Enée E, Rocha B, Chatenoud L, You S.

Elife. 2016 Jan 29;5:e08133. doi: 10.7554/eLife.08133.

38.

Characterization and application of two RANK-specific antibodies with different biological activities.

Chypre M, Seaman J, Cordeiro OG, Willen L, Knoop KA, Buchanan A, Sainson RC, Williams IR, Yagita H, Schneider P, Mueller CG.

Immunol Lett. 2016 Mar;171:5-14. doi: 10.1016/j.imlet.2016.01.003. Epub 2016 Jan 7.

PMID:
26773232
39.

The Notch Ligand DLL4 Defines a Capability of Human Dendritic Cells in Regulating Th1 and Th17 Differentiation.

Meng L, Bai Z, He S, Mochizuki K, Liu Y, Purushe J, Sun H, Wang J, Yagita H, Mineishi S, Fung H, Yanik GA, Caricchio R, Fan X, Crisalli LM, Hexner EO, Reshef R, Zhang Y, Zhang Y.

J Immunol. 2016 Feb 1;196(3):1070-80. doi: 10.4049/jimmunol.1501310. Epub 2015 Dec 28.

40.

Agonists of the TRAIL Death Receptor DR5 Sensitize Intestinal Stem Cells to Chemotherapy-Induced Cell Death and Trigger Gastrointestinal Toxicity.

Finnberg NK, Gokare P, Navaraj A, Lang Kuhs KA, Cerniglia G, Yagita H, Takeda K, Motoyama N, El-Deiry WS.

Cancer Res. 2016 Feb 1;76(3):700-12. doi: 10.1158/0008-5472.CAN-15-2759. Epub 2015 Nov 25.

41.

The PTEN pathway in Tregs is a critical driver of the suppressive tumor microenvironment.

Sharma MD, Shinde R, McGaha TL, Huang L, Holmgaard RB, Wolchok JD, Mautino MR, Celis E, Sharpe AH, Francisco LM, Powell JD, Yagita H, Mellor AL, Blazar BR, Munn DH.

Sci Adv. 2015 Nov 6;1(10):e1500845. doi: 10.1126/sciadv.1500845. eCollection 2015 Nov.

42.

Host immunity contributes to the anti-melanoma activity of BRAF inhibitors.

Knight DA, Ngiow SF, Li M, Parmenter T, Mok S, Cass A, Haynes NM, Kinross K, Yagita H, Koya RC, Graeber TG, Ribas A, McArthur GA, Smyth MJ.

J Clin Invest. 2016 Jan;126(1):402-3. doi: 10.1172/JCI84828. Epub 2015 Nov 23. No abstract available.

43.

A pathogenic role for tumor necrosis factor-related apoptosis-inducing ligand in chronic obstructive pulmonary disease.

Haw TJ, Starkey MR, Nair PM, Pavlidis S, Liu G, Nguyen DH, Hsu AC, Hanish I, Kim RY, Collison AM, Inman MD, Wark PA, Foster PS, Knight DA, Mattes J, Yagita H, Adcock IM, Horvat JC, Hansbro PM.

Mucosal Immunol. 2016 Jul;9(4):859-72. doi: 10.1038/mi.2015.111. Epub 2015 Nov 11.

44.

Bortezomib Improves Adoptive T-cell Therapy by Sensitizing Cancer Cells to FasL Cytotoxicity.

Shanker A, Pellom ST Jr, Dudimah DF, Thounaojam MC, de Kluyver RL, Brooks AD, Yagita H, McVicar DW, Murphy WJ, Longo DL, Sayers TJ.

Cancer Res. 2015 Dec 15;75(24):5260-72. doi: 10.1158/0008-5472.CAN-15-0794. Epub 2015 Oct 22.

45.

CD70 and IFN-1 selectively induce eomesodermin or T-bet and synergize to promote CD8+ T-cell responses.

Dong H, Franklin NA, Ritchea SB, Yagita H, Glennie MJ, Bullock TN.

Eur J Immunol. 2015 Dec;45(12):3289-301. doi: 10.1002/eji.201445291. Epub 2015 Nov 6.

46.

Immunomodulatory effect of peritumorally administered interferon-beta on melanoma through tumor-associated macrophages.

Kakizaki A, Fujimura T, Furudate S, Kambayashi Y, Yamauchi T, Yagita H, Aiba S.

Oncoimmunology. 2015 May 26;4(11):e1047584. eCollection 2015 Nov.

47.

Macrophage Notch Ligand Delta-Like 4 Promotes Vein Graft Lesion Development: Implications for the Treatment of Vein Graft Failure.

Koga JI, Nakano T, Dahlman JE, Figueiredo JL, Zhang H, Decano J, Khan OF, Niida T, Iwata H, Aster JC, Yagita H, Anderson DG, Ozaki CK, Aikawa M.

Arterioscler Thromb Vasc Biol. 2015 Nov;35(11):2343-2353. doi: 10.1161/ATVBAHA.115.305516. Epub 2015 Sep 24. Erratum in: Arterioscler Thromb Vasc Biol. 2016 Mar;36(3):e25.

48.

Sampling of Candida albicans and Candida tropicalis by Langerin-positive dendritic cells in mouse Peyer's patches.

De Jesus M, Rodriguez AE, Yagita H, Ostroff GR, Mantis NJ.

Immunol Lett. 2015 Nov;168(1):64-72. doi: 10.1016/j.imlet.2015.09.008. Epub 2015 Sep 16.

PMID:
26386376
49.

Programmed Death Ligand 1 Promotes Early-Life Chlamydia Respiratory Infection-Induced Severe Allergic Airway Disease.

Starkey MR, Nguyen DH, Brown AC, Essilfie AT, Kim RY, Yagita H, Horvat JC, Hansbro PM.

Am J Respir Cell Mol Biol. 2016 Apr;54(4):493-503. doi: 10.1165/rcmb.2015-0204OC.

PMID:
26378990
50.

Rational Combination of Immunotherapies with Clinical Efficacy in Mice with Advanced Cancer.

Bransi A, Salgado OC, Beffinger M, Milo K, Silina K, Yagita H, Becher B, Knuth A, van den Broek M.

Cancer Immunol Res. 2015 Nov;3(11):1279-88. doi: 10.1158/2326-6066.CIR-15-0103-T. Epub 2015 Jul 3.

Supplemental Content

Loading ...
Support Center